Nuvation Bio Inc. (NUVB): Total Assets
$594.82M
As of 2025-12-31
$744.50M
As of 2026-06-30
-4.0%
3-year compound annual growth
+21.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $594.82M | +10.0% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $540.63M | -13.0% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $621.48M | -7.5% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $672.14M | -13.4% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $776.15M | +249.9% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $221.79M | n/a | 2022-02-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $594.82M | +10.0% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $185.55M | +28.7% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $398.69M | +26.0% |
| Journey Medical Corp (DERM) | 2025-12-31 | $94.59M | +17.9% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $280.73M | -25.5% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $68.92M | -37.7% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $738.36M | -2.9% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $105.01M | -15.4% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.15M | -3.5% |
Compare NUVB, FBIO, TNGX, DERM side by side · Screen every company in Pharmaceutical Preparations ↗